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Oral chemotherapy is a key step towards ‘chemotherapy at home’, a dream of cancer patients, which will
radically change the clinical practice of chemotherapy and greatly improve the quality of life of the patients.
In this research, three types of nanoparticle formulation from commercial PCL and self-synthesized d-α-
tocopheryl polyethylene glycol 1000 succinate (PLA-PCL-TPGS) random copolymer were prepared in this
research for oral delivery of antitumor agents, including thiolated chitosan-modified PCL nanoparticles,
unmodified PLA-PCL-TPGS nanoparticles, and thiolated chitosan-modified PLA-PCL-TPGS nanoparticles. Firstly,
the PLA-PCL-TPGS random copolymer was synthesized and characterized. Thiolated chitosan greatly increases
its mucoadhesiveness and permeation properties, thus increasing the chances of nanoparticle uptake by the
gastrointestinal mucosa and improving drug absorption. The PLA-PCL-TPGS nanoparticles were found by
FESEM that they are of spherical shape and around 200 nm in diameter. The surface charge of PLA-PCL-TPGS
nanoparticles was reversed from anionic to cationic after thiolated chitosan modification. The thiolated
chitosan-modified PLA-PCL-TPGS nanoparticles have significantly higher level of the cell uptake than that of
thiolated chitosan-modified PLGA nanoparticles and unmodified PLA-PCL-TPGS nanoparticles. In vitro cell
viability studies showed advantages of the thiolated chitosan-modified PLA-PCL-TPGS nanoparticles over
TaxolW in terms of cytotoxicity against A549 cells. It seems that the mucoadhesive nanoparticles can increase
paclitaxel transport by opening tight junctions and bypassing the efflux pump of P-glycoprotein. In
conclusion, PLA-PCL-TPGS nanoparticles modified by thiolated chitosan could enhance the cellular uptake and
cytotoxicity, which revealed a potential application for oral chemotherapy of lung cancer.
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Lung cancer continues to be one of the most common
fatal cancers worldwide. Oral chemotherapy is quickly
emerging as an appealing option for cancer patients be-
cause it is less stressful, being that the patient will have
less hospital visits and can still maintain a close relation-
ship with health care professionals [1]. These features
make oral delivery especially attractive for mass im-
munization and self-administration of medications. In
addition, oral chemotherapy could maintain a sustained
moderate concentration of the drug in the circulation to* Correspondence: bmezqq@163.com
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in any medium, provided the original work is pachieve a prolonged exposure of cancerous cells to the
drug as well as to avoid high peak above maximum tole-
rable concentration. This will increase the therapeutic ef-
ficacy and decrease the side effects. However, most
anticancer drugs especially those with excellent antitumor
effects such as paclitaxel are poorly bioavailable. This is
because oral administration of taxoids (paclitaxel and do-
cetaxel) presents an extremely low bioavailability, with a
less than 1% extent of oral absorption [2,3]. The low sys-
temic exposure of oral paclitaxel is, at least in part, due to
their high affinity for P-glycoprotein (P-gp) multidrug ef-
flux pump in the mucosa of the gastrointestinal (GI) tract
[4,5]. P-gp in the mucosa of the gastrointestinal tract may
limit the absorption of the orally administered taxanes and
mediate their direct excretion into the intestinal lumenOpen Access article distributed under the terms of the Creative Commons
g/licenses/by/2.0), which permits unrestricted use, distribution, and reproduction
roperly cited.
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zymes in the gut wall and/or in the liver may also play a
role in the low oral bioavailability of paclitaxel and doce-
taxel [6,7]. Alternative pharmaceutical methods to improve
oral bioavailability of taxoids and other antitumor agents
are currently under intense investigation [2,8-10]. The ge-
neral medical approach is to make use of P-gp/P450 inhi-
bitors such as cyclosporine A to suppress the elimination
process [9,10]. However, cyclosporine A may cause severe
damage to the immune system of the body and, thus,
create severe complications during cancer treatment. Poly-
meric nanoparticles are highly attractive from the pharma-
ceutical point of view due to their desirable properties
such as biocompatibility, biodegradability, and controlled
release. Furthermore, polymeric nanoparticles could avoid
recognition by the P-gp efflux pump and, thus, have a
strong potential to enhance the oral bioavailability of
poorly absorbed drugs [11-13]. Their small size and their
large specific surface area favor their absorption compared
to larger drug carriers. In addition, polymeric nanoparticles
can protect encapsulated drugs from luminal degradation
as well as gut-wall metabolism [8]. Moreover, they could
reduce the multi-drug resistance (MDR) that characterizes
many anticancer drugs by a mechanism of internalization
of the drug, reducing its efflux from cells mediated by the
P-gp. It seems to be commonly accepted that particle sur-
face properties are utmostly important for their uptake by
intestinal epithelial cells. Therefore, many methodologies
and innovative techniques have been developed to enhance
the intestinal absorption of particles, either by altering
their surface properties or by conjugating a targeting mo-
lecule at their surface [14]. In this research, our group
proposed a new type of polymeric nanoparticles, i.e., bio-
degradable poly(lactide-co-ε-caprolactone)-d-α-tocopheryl
polyethylene glycol 1000 succinate (PLA-PCL-TPGS) na-
noparticles modified with thiolated chitosan for oral che-
motherapy using paclitaxel as a therapeutic agent due to
its high therapeutic efficacy against a broad spectrum of
tumors and its great commercial success as one of the
best-selling antitumor therapeutic drugs.
Chitosan, a linear polysaccharide derived from chitin
obtained from crustacean shells, has emerged as a useful
drug delivery matrix because of it polycationic nature, bio-
degradability, biocompatibility, mucoadhesiveness, and
ease of physical and chemical modification [15]. The inter-
action between cationic amino groups on chitosan and
anionic moieties such as sialic and sulfonic acids on the
mucus layer is responsible for its mucoadhesiveness [16].
In addition, chitosan enhances epithelial permeability
through the opening of tight junctions between epithelial
cells [17]. Recently, it was reported that the covalent at-
tachment of thiol groups to polymers greatly increases
their mucoadhesiveness and permeation properties with-
out affecting biodegradability [16,18]. Thiolated chitosan-modified nanoparticles are expected to be appropriate
carriers for oral absorption of drugs [19-21]. Thiolated
chitosan has many advantages as a carrier in nanoparticu-
late drug delivery systems. It is nontoxic, biocompatible,
and biodegradable and has been proven to control the re-
lease of drugs, proteins, and peptides. It is soluble in aque-
ous media, avoids the use of organic solvents, and does
not require further purification of nanoparticles [22].
Thus, thiolated chitosan was used in the present study to
be absorbed on the nanoparticle surface by electrostatic
forces of attraction between positive and negative charges.
In this research, PLA-PCL was used to maintain the desi-
rable mechanical strength of the polymer. Vitamin E d-α-
tocopheryl polyethylene glycol 1000 succinate (Vitamin E
TPGS, or simply TPGS) is a water-soluble derivative of
naturally sourced vitamin E, which is formed by esterifica-
tion of vitamin E succinate with polyethylene glycol 1000.
Previous studies revealed that TPGS was able to improve
drug permeability across biological membranes by inhi-
bition of P-gp pumps and, thus, increase the drug absorp-
tion capability and decrease P-gp-mediated MDR in
cancer cells [23-25]. In addition, TPGS was able to effect-
ively inhibit the growth of human lung cancer cells in cell
culture and in animal models [26]. The superior antitumor
activity of TPGS is mainly due to its increasing ability to
induce apoptosis in tumor cells [26-28]. A few studies
have shown synergistic effects of combinations of TPGS
with other antitumor drugs [27]. Furthermore, it has been
found that TPGS-emulsified nanoparticles had higher en-
capsulation efficacy and cellular uptake, longer half-life,
and higher therapeutic efficiency of the formulated drug
than those emulsified by poly(vinyl alcohol), a commonly
used emulsifier in nanoparticle formulation process [24].
Thus, we were inspired to fabricate a novel thiolated
chitosan-modified PLA-PCL-TPGS nanoparticle as oral
anticancer drug carrier for lung cancer chemotherapy.
The chemical structure of PLA-PCL-TPGS random co-




and d-α-tocopheryl polyethylene glycol 1000 succinate
(C33O5H54 (CH2CH2O)23) were purchased from Sigma-
Aldrich (St. Louis, MO, USA). ε-caprolactone (CL) were
obtained from Acros Organics (Geel, Belgium). Thiolated
chitosan (Mw 33000 Da) was from NanoMed Biotech Co.
Ltd (Shenzhen, China). Poly(ε-caprolactone) (PCL) (MW
42000 Da), and stannous octoate (Sn(OOCC7H15)2) were
also purchased from Sigma (St. Louis, MO, USA). Pac-
litaxel powder of purity 99.9% was from BioOne Biotech
Co. Ltd (Shenzhen, China). Fetal bovine serum was
received from Gibco (Life Technologies, AG, Switzerland).
Methanol and acetonitrile were obtained from EM
Figure 1 Chemical structure and 1H-NMR spectra of PLA-PCL-TPGS copolymer. (A) Chemical structure of PLA-PCL-TPGS copolymer;
(B) typical 1H-NMR spectra of PLA-PCL-TPGS copolymer.
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produced by Millipore Water Systems (Millipore Corpo-
ration, Billerica, USA) was utilized throughout all ex-
periments.
Synthesis and characterization of PLA-PCL-TPGS random
copolymer
PLA-PCL-TPGS random copolymers were synthesized
from ε-caprolactone, lactide, and TPGS in the presence of
stannous octoate as a catalyst via ring opening poly-
merization. In short, pre-weighted amounts of ε-caprolac-
tone, lactide, TPGS, and one drop of stannous octoate
were added in a flask. The mixture was heated to 145°C
and allowed to react for approximately 16 h. Synthesis
was carried out under an oxygen- and moisture-free envi-
ronment. The product was dissolved in dichloromethane
(DCM) and then precipitated in excess cold methanol to
remove unreacted monomers and TPGS. The final pro-
duct was collected by filtration and dried under vacuum.
The TPGS content and number-averaged molecular
weight of the copolymer was determined by 1H NMR in
CDCl3 at 300 Hz (Bruker ACF300, Bruker AXS Pte Ltd.,
Singapore).
Preparation of thiolated chitosan-modified paclitaxel-
loaded nanoparticles
Nanoparticles were prepared by a modified solvent extrac-
tion/evaporation technique [29,30]. In brief, 11 mg of
paclitaxel powder and 100 mg of PLA-PCL-TPGS copoly-
mer were weighed and dissolved in 6 ml DCM. The or-
ganic solution was immediately poured into 100 ml of
0.03% (w/v) TPGS solution under mild stirring. The mix-
ture was then sonicated for 90 s at 30 W output to form
water-in-oil emulsion. The emulsion was further evapo-
rated under ambient conditions overnight to removeDCM. The nanoparticles were harvested by centrifugation
at 80,000×g for 15 min and then washed three times to re-
move the emulsifiers and unentrapped drug. The resulting
nanoparticles were finally resuspended in 5 ml of deio-
nized water and lyophilized. The PLA-PCL-TPGS nano-
particles was further modified by thiolated chitosan using
a method described previously [31]. Preweighed thiolated
chitosan was dissolved in deionized water at a concentra-
tion of 0.5 mg/ml. The nanoparticles were suspended in
thiolated chitosan solution at a concentration of 9.5 mg/ml
by sonication at 30 W power output for 30 s in an ice
bath, and then were collected by centrifugation at
80,000×g for 15 min. The coumarin-6-loaded nanoparti-
cles were prepared by encapsulation of 0.1% (w/v)
coumarin-6 instead of paclitaxel. Thiolated chitosan-
modified PCL nanoparticles were fabricated by the same
procedure.
Characterization of nanoparticles
Particle size and zeta potential
Particle size and size distribution of nanoparticles
were measured using dynamic light scattering on a
Malvern Zetasizer Nano-ZS90 (Malvern Instruments,
Worcestershire, UK). The lyophilized nanoparticles were
diluted with DI water before measurement. Surface charge
of the nanoparticles was determined by laser Doppler
anemometry using a Zetasizer Nano Series (Malvern
Instruments). All measurements were done in triplicate.
Surface morphology
The morphology of nanoparticles was characterized by
field emission scanning electron microscopy (FESEM;
ZEISS 77 SUPRA 40VP, Carl Zeiss, Co., Ltd., Shanghai,
China) at 5.0 kV electron high tension. To prepare sam-
ples for the FESEM observations, a drop of the particle
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natant liquid was removed with a capillary after the parti-
cles were allowed to settle. The particles were then coated
with platinum layer for 30 s.
Drug loading and encapsulation efficiency
The encapsulation efficiency (EE) and the actual drug
loading of the nanoparticles were measured by high-
performance liquid chromatography (LC 1100, Agilent
Technologies, Santa Clara, USA) as described before
[31,32]. In short, dried nanoparticles (5 mg) were dis-
solved in 1 ml of methylene chloride under vigorous vor-
tex. The organic solution was transferred to 5 ml of
mobile phase consisting of acetonitrile and deionized
water (50:50, v/v). Methylene chloride was evaporated
under a nitrogen stream until a clear solution obtained.
The samples were then used for high-performance liquid
chromatography (HPLC) analysis. The column effluent
was monitored at 227 nm with a UV–vis detector. The
standard size HPLC column (4.6 × 250 mm) is run at a flow
rate of 1 mL/min. The drug encapsulation efficiency was
defined as the percentage of the drug loaded in the final
product. All these experiments were done in triplicates.In vitro drug release
Accurately weighted aliquots of drug-loaded nanoparticles
(15 mg) were suspended in 5 ml release medium (PBS pH
7.4 containing 0.1% w/v Tween 80). The use of Tween 80
in the release media was able to increase the solubility of
drug in the PBS and avoided the binding of drug to the
tube wall. The nanoparticle suspension was transferred
into a dialysis tubing membrane which is sealed at one
end with a clamp. The sealed dialysis bag was placed into
a centrifuge tube and immersed in 15-ml release medium.
The centrifuge tube was placed in an orbital water bath
shaking at 130 rpm at 37.0°C. A 10 ml aliquots of samples
was periodically removed for HPLC analysis and replaced
with fresh medium. The samples were extracted with 2 ml
methylene chloride and reconstituted in 5 ml mobile
phase. Methylene chloride was evaporated under a nitro-
gen stream until a clear solution was obtained. The ana-
lysis procedure was the same as for the determination of
drug EE.
In vitro cellular uptake of nanoparticles
Caco-2 cells which were obtained from the American
Type Culture Collection (Manassas, USA) were used in
this research to simulate the gastrointestinal barrier for
oral chemotherapy. The cells were grown in tissue culture
flasks maintained at 37°C in a humidified, 5% CO2 atmos-
phere. The medium, Dubelco's modified essential medium
(DMEM) supplemented with 100 μg/ml streptomycin and
20% fetal bovine serum, was freshened once every 3 days.After reaching 70% to 90% confluence, the cells were har-
vested with 0.25% of trypsin-EDTA solution (Invitrogen,
Corporation, Grand Island, USA) and cultured in
96-well black plate (Corning Inc., Corning, USA) at the
density of 1.3 × 104 cells per well; when the cells reached
confluence, the cells were equilibrated with HBSS buffer at
37°C for 60 min and then incubated with coumarin-6-
loaded nanoparticle suspension medium. The nanoparticles
were well-dispersed in the culture medium at concentra-
tions of 100, 250, and 500 μg/ml. Nanoparticle dispersions
were incubated at 37°C in a 5% CO2 atmosphere for 2 h.
After incubation with the corresponding nanoparticles, the
suspension was removed from the wells, and the cell
monolayers were rinsed three times with 50 μl cold PBS
(pH 7.4) to remove any traces of nanoparticles left in the
wells. After that, the cells were lysed with 50 μl of 0.5%
(w/v) Triton-X 100 in 0.2 N NaOH solution (Sigma-
Aldrich, MO, USA). The fluorescence intensity presented in
each well was then measured on a GENios Lueifcrase micro-
plate reader (Tecan Group Ltd., Männedorf, Switzerland)
with excitation wavelength at 430 nm and emission wave-
length at 485 nm. Cellular uptake efficiency was expressed
as the percentage of cell-associated fluorescence vs. that
present in the positive control. Culture of human lung
cancer cell lines A549 cells and their uptake of the
coumarin-6-loaded nanoparticles were performed using
the same procedure.
Caco-2 cells were reseeded in the Lab-Tek chambered
cover glass system (Nalge Nunc International, Rochester,
USA). After the cells were incubated with 250 μg/ml
coumarin-6-loaded thiolated chitosan-modified PLA-
PCL-TPGS particle suspension at 37°C for 2 h, the cells
were rinsed with cold PBS buffer for three times and
then fixed with 70% ethanol solution for 20 min. The
cells were further rinsed twice with PBS and then
counter-stained with 4′,6-diamidino-2-phenylindole
dihydrochloride (DAPI; Fluka, Buche, Switzerland) for
the visualization of the cell nuclei. The cell monolayer
was rinsed twice with PBS solution and mounted using the
Dako fluorescent mounting medium (Dako, Carpinteria,
USA) to be observed by confocal laser scanning microscope
(CLSM; Olympus Fluoview FV-1000, Olympus Optical.
Co., Ltd., Tokyo, Japan). The images of the cells were deter-
mined with differential interference contrast channel, and
the images of coumarin-6-loaded nanoparticles and the
nuclei of the cells stained by DAPI were recorded with the
following channels: blue channel (DAPI) with excitation at
340 nm and green channel (coumarin-6) with excitation at
488 nm.
Cell viability assay
A549 cells were counted and seeded in 96-well plates at
a density of 0.5 × 104 cells per well and incubated over-
night to allow cell attachment. The cells were incubated
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pension, thiolated chitosan-modified PLA-PCL-TPGS
nanoparticles, and TaxolW (Bristol-Myers Squibb, New
York, USA) at 0.25, 2.5, 12.5, and 25 μg/ml equivalent
paclitaxel concentrations and blank thiolated chitosan-
modified PLA-PCL-TPGS nanoparticles with the same
amount of nanoparticles for 24, 48, and 72 h, respec-
tively. At the determined time, the formulations were
replaced with fresh DMEM containing MTT (5 mg/ml),
and the cells were then incubated for additional 4 h.
MTT-containing medium was aspirated off, and 150 ml
of DMSO was added to dissolve the formazan crystal
formed by living cells. The absorbance at 570 nm was
measured by a microplate reader (Model 680, Bio-Rad
Laboratories, Hertfordshire, UK). Untreated cells were
taken as a control with 100% viability, and cells without
the addition of MTT were used as blank to calibrate the
spectrophotometer to zero absorbance. IC50 values
(concentration required to reduce cells viability by 50%
as compared to the control cells) for each sample was
calculated by curve fitting of the cell viability data. The
results are expressed as mean ± SD of one representative
experiment performed in triplicate, and the experiments
were performed three times.Ex vivo study
The everted sac method was chosen for the measurement
of transportation of paclitaxel across the intestine barrier.
It was carried out according to the slightly modified me-
thod that was described previously [33], as follows.
First, a section of about 5 cm of the jejunum was re-
moved from a male rat under ketamine (50 mg/kg) and
chlorpromazine (10 mg/kg) anesthesia and washed with
Krebs-Ringer bicarbonate solution of pH = 7.4. This sec-
tion was then gently inverted with a glass rod, and a tube
was inserted in one side of the section and tied securely
with tape. The other side of the intestine was tied, and 1
mL Krebs-Ringer bicarbonate solution was poured
through the hypodermic needle in the tube. The gut sac
was placed in a medium saturated with 95% O2, 5% CO2,
and contained the test sample in Krebs-Ringer bicarbon-
ate solution at 37°C. The test samples used include:
(1) paclitaxel (1 mg) as TaxolW, and (2) thiolated chitosan-Table 1 Effects of thiolated chitosan modification on size, enc
Group Polymer Size (nm) PDI Zeta potential (mV
CNP PCL 203.56 ± 4.35 0.335 −19.63 ± 4.10
UNP PLA-PCL-TPGS 198.46 ± 2.49 0.246 −18.29 ± 3.25
TNP PLA-PCL-TPGS 206.15 ± 3.66 0.286 24.66 ± 4.19
DNP PLA-PCL-TPGS 219.33 ± 4.25 0.317 26.18 ± 5.02
PDI polydispersity index; EE drug entrapment efficiency; n = 3.modified PLA-PCL-TPGS nanoparticles (equivalent to 1
mg of paclitaxel). In absorption studies, an O2 and CO2
mixture was bubbled into the intestinal mucosa to obtain
intestinal peristaltic movement. At certain periods of time,
0.5-mL samples were drawn from inside the intestine and
replaced with the same volume of fresh medium. The
amount of transported paclitaxel in the samples was mea-
sured by the HPLC method.Statistical analyses
Data were presented as the mean ± SD. Student's t test
was used to assess the differences between means. A
P value <0.05 was considered to indicate a significant
difference.Results and discussions
Synthesis and characterization of PLA-PCL-TPGS ran-
dom copolymer.
The structure of the synthesized PLA-PCL-TPGS co-
polymer was detected by 1H NMR in CDCl3. Figure 1
shows the chemical structure of PLA-PCL-TPGS random
copolymer and 1H NMR spectroscopy of the PLA-PCL-
TPGS copolymer. The signals at 5.2 and 1.69 ppm (peaks
a and e) were assigned to the CH protons and methyl pro-
tons -CH3 of PLA segment, respectively. The peak at 3.65
ppm (peak c) was assigned to the -CH2 protons of PEO
part of TPGS. The lower peaks in the aliphatic region be-
long to various moieties of vitamin E tails. The peaks at
4.06 (peak b), 2.31 (peak d), 1.60 to 1.70 (peak e), and 1.35
to 1.43 (peak f) were assigned to -OCH2, -COCH2, -CH2
(4 H), and -CH2 (2 H) segments of PCL, respectively [24].
The molecular weight of the PLA-PCL-TPGS was calcu-
lated using the ratio between the peak areas at 4.06 (peak
area 9.64), 5.2 (peak area 1.23), and 3.65 (peak area 3.00).
The number-averaged molecular weight of the PLA-PCL-
TPGS random copolymer was determined to be 33,229.
The feeding ratios of ε-caprolactone, lactide, and TPGS
molecular mass were 75%, 15%, and 10%, respectively.
However, the ratios of ε-caprolactone, lactide, and TPGS
molecular mass which were integrated into the PLA-PCL-
TPGS copolymers were 87.18%, 8.17%, and 4.64%.apsulation efficiency, and zeta potential





Figure 2 FESEM image of paclitaxel-loaded 5% thiolated
chitosan-modified PLA-PCL-TPGS nanoparticles.
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Size, zeta potential, and encapsulation efficiency
The particle size data of the 5% thiolated chitosan-modified
PCL nanoparticles (CNP), unmodified PLA-PCL-TPGS
nanoparticles (UNP), 5% thiolated chitosan-modified
PLA-PCL-TPGS nanoparticles (TNP), and 20% thiolated
chitosan-modified PLA-PCL-TPGS nanoparticles (DNP)
fabricated in this research are presented in Table 1. The
particle size was found to be an important parameter
regarding particle uptake. The small nanoparticle size may
provide a large surface area and increase in mucin adsorp-
tion, which leads to a high mucoadhesive property for the
nanoparticles [34]. The permeability of the particles
through the intestinal mucosa decreases with increasingFigure 3 The in vitro release profiles of paclitaxel-loaded CNP, UNP, Tparticle size reaching a cut-off at around 500 nm [35,36].
The average diameter of the resulted nanoparticles was
around 200 nm, which is in the size range favoring the in-
testinal uptake of the nanoparticles [2,8]. The results also
showed that the addition of thiolated chitosan resulted in
a slight increase in particle size. Zeta potential analysis
confirmed that surface modification with 5% thiolated
chitosan reversed the PLA-PCL-TPGS nanoparticles from
a negative surface charge of −18.29 mV to a significantly
positive charge of +24.66 mV. As reported in the litera-
ture, positive surface charge could enhance the mucosal
uptake due to anionic nature of mucous layer [37].
Regarding the drug EE, it can be seen from Table 1
that the 5% thiolated chitosan-modified PLA-PCL-
TPGS nanoparticles achieved much higher EE than the
5% thiolated chitosan-modified PCL nanoparticles.
This might be contributed to the self-emulsification
effect of TPGS segment in the PLA-PCL-TPGS copoly-
mer [2,8].
Surface morphology
Surface morphology of the 5% thiolated chitosan-
modified PLA-PCL-TPGS nanoparticles was inspected
by FESEM. Figure 2 shows the FESEM image of 5% thio-
lated chitosan-modified PLA-PCL-TPGS nanoparticles.
The FESEM image further confirmed the particle size
determined by laser light scattering. The morphology of
the nanoparticles exhibited well-formed spherical shape
with rough surface.
In vitro drug release assay
The in vitro drug release profiles of the CNP, UNP, and
TNP in the first 32 days are presented in Figure 3. TheNP.
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66.59% of the encapsulated drug in the first 5 days and
after 32 days, respectively, which was much faster than
the CNP, which was only 20.10% and 38.00%, respect-
ively, in the same periods. The faster drug release of
TNP may be attributed to the lower molecular weight
and the higher hydrophilicity of PLA-PCL-TPGS copoly-
mer in comparison with the PCL nanoparticles. It causes
the copolymer to swell and to degrade faster, thus pro-
moting the drug release from the nanoparticles. It can
also be seen from Figure 3 that drug release from the
TNP was slightly slower than that of UNP. Such a
phenomenon may be attributed to slightly smaller par-
ticle size of UNP.Figure 4 Cellular uptake of coumarin-6-loaded CNP, UNP, TNP by (A)Uptake of coumarin-6-loaded nanoparticles by Caco-2 and
A549 cells
Caco-2 colonic cell line is a widely accepted model to pre-
dict the permeability and absorption of compounds in
humans [38]. Paclitaxel (Taxol) has been shown to be ef-
fective in metastatic lung cancer as a single agent and in
combination with other cytotoxic drugs. The fluorescence
uptake by the A549 cells could provide a useful model to
assess the in vitro therapeutic effect of paclitaxel in the
various formulations for lung cancer treatment [39,40].
The cellular uptake of coumarin-6-loaded CNP, UNP, and
TNP was thus evaluated in this research using Caco-2 cell
line as in vitro model of the GI barrier and A549 cell line
as model cancer cells. The cellular uptake efficiency of theCaco-2 and (B) A549 cells after 2-h incubation.
Figure 5 CLSM images of Caco-2 cells after 2-h incubation with coumarin-6-loaded 5% thiolated chitosan-modified PLA-PCL-TPGS
nanoparticles at 37.0°C. The cells were stained by DAPI (blue), and the coumarin-6-loaded nanoparticles are green. The cellular uptake was
visualized by overlaying images obtained by EGFP filter and DAPI filter: left image from EGFP channel (A), center image from DAPI channel (B),
right image from combined EGFP channel and DAPI channel (C).
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cells was assayed upon 2-h incubation, and the results are
shown in Figure 4.
It can be obtained from Figure 4A that there is an in-
creasing trend in the Caco-2 cellular uptake: TNP > CNP
> UNP. The TNP resulted in 1.45-, 1.61-, and 1.67-fold
higher cellular uptakes than those of CNP, and 1.48-, 1.72-,
and 1.72-fold higher cellular uptakes than those of UNP at
the incubated particle concentration of 100, 250, and 500
μg/ml, respectively. Figure 4A also shows that the cellular
uptake was particle concentration-dependent.
Figure 4B shows that the cellular uptake efficiency of the
coumarin-6-loaded TNP by A549 cells is higher than that
of CNP and UNP, which is also found to be dose-
dependent. The TNP resulted in 1.49-, 1.68-, and 1.93-
fold higher cellular uptakes than those of CNP, and
1.31-, 1.36-, and 1.65-fold higher cellular uptakes than
those of UNP at the incubated particle concentration of
100, 250, and 500 μg/ml, respectively. The positive sur-
face charge of thiolated chitosan provided the incentive
to aid drug delivery, since it is expected to ensure better
interaction with the negatively charged cell membrane
[31,41,42]. This resulted in increased retention time at
the cell surface, thus increasing the chances of particle
uptake and improving oral drug bioavailability [43].Figure 6 Viability of A549 cells. After 24 (A), 48 (B), and 72 (C) hour cell
with that of TaxolW at the same paclitaxel dose (n = 6).Figure 5 shows CLSM images of Caco-2 cells after 2 h
incubation with the coumarin-6-loaded 5% thiolated
chitosan-modified PLA-PCL-TPGS nanoparticles at 250
μg/ml nanoparticle concentration. The images obtained
were (A) the enhanced green fluorescent protein (EGFP,
green) channel, (B) the DAPI (blue) channel, (C) the
overlay of the two channels. It can be observed from
Figure 5 that the fluorescence of the coumarin-6-loaded
5% thiolated chitosan-modified PLA-PCL-TPGS nano-
particles (green) is located in the cytoplasm around the
nucleus (blue, stained by DAPI), indicating that the
coumarin-6-loaded nanoparticles have been internalized
into the cells [44].
Assessment of modified nanoparticle cytotoxicity
Figure 6 shows the viability of A549 cancer cells after 24-,
48-, and 72-h cell culture with paclitaxel formulated in the
CNP, UNP, and TNP, respectively, in comparison with that
of the TaxolW formulation at the same 0.025, 0.25, 2.5, 10,
and 25 μg/ml paclitaxel dose (n = 6). It can be concluded
from Figure 6 that all three nanoparticle formulations
showed advantages in decreasing the cancer cell viability
(i.e., increasing the cancer cell mortality) versus the
current clinical dosage form TaxolW, and the TNP can
have even better effects than UNP. For example, the A549culture with paclitaxel formulated in CNP, UNP, and TNP in comparison
Table 2 IC50 of A549 cells after 24-, 48-, 72-h incubation





CNP UNP TNP TaxolW
24 2.035 0.958 0.201 2.609
48 1.748 0.634 0.122 1.645
72 0.692 0.325 0.106 0.910
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concentration was 44.41% for TaxolW, and 28.65% (i.e., a
28.39% increase in cytotoxicity) for TNP. Furthermore,
compared with TaxolW, the cytotoxicity of A549 cells was
increased by 37.65% (p < 0.05, n = 6) and 18.72% (p <
0.05, n = 6) for TNP after 48- and 72-h incubation at
10 μg/ml drug concentration. Such advantages of the
nanoparticle formulations may be due to the effects of
thiolated chitosan and TPGS component of the nanoparti-
cles in enhancing cellular uptake of the nanoparticles. The
advantages in cancer cell viability of the TNP > UNP > the
TaxolW formulation is dependent on the incubation time.
This may be due to the controlled release manner of the
nanoparticle formulation. The advantages in cancer cell
viability of the TNP > UNP > the TaxolW formulation is
also dependent on the drug concentration. The higher the
drug concentration, the more significant effects would be
obtained.
The advantages in cytotoxicity of the TNP > UNP >
TaxolW can be quantitatively analyzed by IC50, which can
be determined by constructing a dose–response curve.
Table 2 shows IC50 values of A549 cells after 24-, 48-,
72-h incubations with paclitaxel formulated in CNP, UNP,Figure 7 Profile of the amount of paclitaxel transported in medium (pTNP, and TaxolW, respectively, which are obtained from
Figure 6. The data showed that the IC50 values for A549
cells were reduced from 2.609, 1.645, and 0.910 to 0.201,
0.122, and 0.106 μg/ml for TNP after 24, 48 and 72 h, re-
spectively. As time goes on, the TNP showed better IC50
values and better in vitro therapeutic effects for A549 cells
than commercial TaxolW. This is because the cumulative
release of paclitaxel was only 22.63%, 26.52%, and 32.45%
for TNP after 24, 48 and 72 h (Figure 3), respectively, and
the release started from zero while the commercial TaxolW
immediately became 100% available for the A549 cells in
culture. Moreover, the degradation of PLA-PCL-TPGS
random copolymer may release the TPGS components,
which have synergistic antitumor activity in the presence
of antitumor drugs [27,28], thus increasing cancer cell
mortality. Hasegawa et al. [45] reported a growth-
inhibitory effect of chitosan on tumor cells. The growth
inhibition was examined by WST-1 colorimetric assay and
cell counting. They also observed DNA fragmentation
(which is a characteristic of apoptosis) and elevated
caspase-3-like activity in thiolated chitosan-treated cancer
cells. Chitosan induced apoptosis via caspase-3 activation
in lung tumor cells [45]. Therefore, thiolated chitosan may
also increase cancer cell mortality and have synergistic
antitumor activity in the presence of antitumor agents and
TPGS.
Ex vivo study
In this study, we used the everted intestinal sac method
for measuring the transporting of paclitaxel from the in-
testinal barrier. Figure 7 shows the amount of paclitaxel
transported across the intestinal barrier. As seen in the
figure, after 120 min, the amount of paclitaxel transportedH 7.4). Experiments were carried out in triplicate (n = 3).
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cantly higher than free paclitaxel. Consequently, on the
basis of these results, it was hypothesized that the trans-
portation of paclitaxel across the intestine membrane is
low, and the mucoadhesive NPs can increase paclitaxel
transport by opening tight junctions and bypassing the ef-
flux pump of P-gp.
Conclusions
Three types of nanoparticles were developed from bio-
degradable self-synthesized PLA-PCL-TPGS random
copolymer and commercial PCL for oral delivery of anti-
tumor agents with paclitaxel employed as a model drug,
including CNP, UNP, and TNP. The design of the nano-
particle matrix material was made to take full advantages
of TPGS in nanoparticle fabrication process such as high
emulsification effects and high encapsulation efficiency, as
well as improvement of therapeutic effects such as the re-
duction of P-gp-mediated MDR and superior antitumor
efficacy. Thiolated chitosan could greatly increase its
mucoadhesiveness and permeation properties, thus in-
creasing the chances of nanoparticle uptake by the gastro-
intestinal mucosa and improving drug absorption. The
data showed that the thiolated chitsoan-modified PLA-
PCL-TPGS nanoparticles have significantly higher level of
the cell uptake than that of thiolated chitosan-modified
PCL nanoparticles and unmodified PLA-PCL-TPGS
nanoparticles. In vitro cell viability studies showed advan-
tages of the thiolated chitosan-modified PLA-PCL-TPGS
nanoparticles over commercial TaxolW in terms of cyto-
toxicity against A549 cells. It seems that the mucoadhesive
nanoparticles can increase paclitaxel transport by opening
tight junctions and bypassing the efflux pump of P-gp. In
short, oral chemotherapy by thiolated chitosan-modified
PLA-PCL-TPGS nanoparticle formulation is an attractive
alternative approach to the treatment of lung cancer.
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